%0 Journal Article %T Clinical Trial of Medicinal Synthetic Aluminum-Magnesium Silicate (Antivirt®) on Viral Loads and CD4-Lymphocytes Counts of HIV/AIDS Patients %A Maduike C. O. Ezeibe %A Dahiru Aleeyu %A Ijeoma J. Ogbonna %A Ekenma Kalu %J World Journal of AIDS %P 37-41 %@ 2160-8822 %D 2016 %I Scientific Research Publishing %R 10.4236/wja.2016.62005 %X For clinical trial of Medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt®), on viral loads and CD4-lymphocytes counts of HIV/AIDS patients, 10 volunteers were treated. Their blood samples were tested for viral loads and for CD4-lymphocytes counts, before the treatment and every 4 weeks during the medication. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra protection® (1 tablet/day), for 4 weeks. Then, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When their viral loads become undetectable, they would be treated for additional 4 weeks. Initially, the Antivirt®-regimen appeared to worsen both HIV infection-load and immune deficiency but later relieved them. Patients¡¯ mean-viral load increased (P = 0.020), from 1820.30 ¡À 868.75 to 2855.90 ¡À 960.98, after 4 weeks before reducing (P = 0.030) to 1565.20 ¡À 743.17, after 8 weeks. Similarly, their mean-CD4-lymphocytes count reduced (P = 0.008) from 496.80 ¡À 194.39 to 263.90 ¡À 149.26, after 4 weeks before improving (P = 0.001) to 507.90 ¡À 133.19, after 8 weeks. %K Antivirt< %K sup> %K & %K reg %K < %K /sup> %K Nanoparticles %K Destroying Infected Cells %K Unmasking ¡°Hidden Infections¡± %K Mopping-Out HIV %U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=65803